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The healthy heart comprises many different cell types that work together to preserve 
optimal function. However, in a diseased heart the function of one or more cell types 
is compromised which can lead to many adverse events, one of which is myocardial 
infarction (MI). Immediately after MI, the cardiac environment is characterized by exces-
sive cardiomyocyte death and inflammatory signals leading to the recruitment of macro-
phages to clear the debris. Proliferating fibroblasts then invade, and a collagenous scar 
is formed to prevent rupture. Better functional restoration of the heart is not achieved due 
to the limited regenerative capacity of cardiac tissue. To address this, biomaterial therapy 
is being investigated as an approach to improve regeneration in the infarcted heart, as 
they can possess the potential to control cell function in the infarct environment and limit 
the adverse compensatory changes that occur post-MI. Over the past decade, there has 
been considerable research into the development of biomaterials for cardiac regeneration 
post-MI; and various effects have been observed on different cell types depending on the 
biomaterial that is applied. Biomaterial treatment has been shown to enhance survival, 
improve function, promote proliferation, and guide the mobilization and recruitment of 
different cells in the post-MI heart. This review will provide a summary on the biomaterials 
developed to enhance cardiac regeneration and remodeling post-MI with a focus on how 
they control macrophages, cardiomyocytes, fibroblasts, and endothelial cells. A better 
understanding of how a biomaterial interacts with the different cell types in the heart may 
lead to the development of a more optimized biomaterial therapy for cardiac regeneration.
Keywords: biomaterials, myocardial infarction, cell response, cardiac regeneration, fibroblasts, macrophages, 
endothelial cells, cardiomyocytes
iNTRODUCTiON
Myocardial infarction
Cardiovascular disease (CVD) is defined as a physiological condition that causes impaired function 
of the heart or blood vessels of the circulatory system. Myocardial infarction (MI) is often the 
consequence of prolonged CVD and results from the blockage of one or more coronary arteries 
causing ischemia (lack of oxygen and nutrients due to loss of blood supply) to the myocardium 
(Frangogiannis, 2008; Rane and Christman, 2011). The ischemic event triggers a switch from 
TABLe 1 | List of material abbreviations.
Biomaterial Abbreviation
Hydroxyethyl methacrylate hyaluronic acid HEMA-HA
Poly(lacto-co-glycolic acid) PLGA
QHREDGS/collagen + chitosan QHG213H
Polyethylene glycol PEG
poly δ-valeracetone PVL
RADA16-II + jagged1 RJ
Polypyrrole PPy
Small intestinal submucosal ECM SIS-ECM
Poly(ε-caprolacetone) PCL
Poly(ε-caprolacetone)-2-HEMA and 
poly(N-isopropylacrylamide)
Dex-PCL-HEMA/PNIPAAm 
Tetronic fibrinogen TF
PEG fibrinogen PF
Ascorbic acid AA
Carboxylated PCL cPCL
Polydioxanone PDO
Poly-lactic acid PLC
Poly(l-lactide-co-ε-caprolacetone) P(LLA-CL)
Poly(N-isopropylacrilamide-co-propylacrylic acid-
co-propyl acrylate)
p(NIPAAm-co-PAA-co-BA)
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aerobic to anaerobic respiration leading to acidosis from lactic 
acid accumulation, the generation of reactive oxygen species 
(ROS), and a significant loss of cardiac myocytes (Dzau et  al., 
2006; Jourdan-Lesaux et al., 2010). The post-MI heart undergoes 
a complex multiphase healing process, involving three overlap-
ping phases: the inflammatory, proliferation, and maturation 
phases (Pfeffer and Braunwald, 1990; Frangogiannis, 2006, 2008, 
2012b; Fraccarollo et al., 2012) (Figure 1). In the inflammatory 
phase, apoptotic and necrotic cardiomyocytes release cytokines 
that signal for the recruitment of neutrophils and monocytes 
(Fraccarollo et  al., 2012). Upon arrival of these immune cells 
to the ischemic tissue, there is a cascade of neurohormonal and 
intracellular signaling events that further mobilizes and activates 
more immune cells, namely neutrophils and macrophages, 
to remove debris from the infarct area (Frangogiannis, 2008; 
Fraccarollo et  al., 2012; Sutton and Sharpe, 2015). After the 
removal of cellular debris, macrophages release growth factors 
and cytokines leading to the maturation of granulation tissue 
through angiogenesis and the promotion of fibroblast prolifera-
tion, marking the beginning of the transition from the inflam-
matory phase to the proliferation phase (Pfeffer and Braunwald, 
1990; Fraccarollo et  al., 2012). During the proliferative phase, 
fibroblasts migrate into the infarct where they respond to TGF-
β1, fibronectin extra domain A, and mechanical tension causing 
them to undergo a phenotypic change to myofibroblasts (van 
den Borne et  al., 2010; Dobaczewski et  al., 2011; Fraccarollo 
et  al., 2012; Sutton and Sharpe, 2015). During the maturation 
phase, these “new” myofibroblasts, which have many smooth 
muscle-like qualities including the ability to contract, secrete 
large amounts of extracellular matrix (ECM) proteins, primarily 
collagen, into the infarct. The deposition of ECM forms the col-
lagenous scar, which serves as mechanical support to protect the 
heart from ventricular rupture and is termed reparative fibrosis 
(Fraccarollo et al., 2012; Sutton and Sharpe, 2015). Although this 
scar is necessary to prevent rupture, maturation of the scar intro-
duces its own pathophysiologic complications. Initially, there is 
apoptosis of fibroblasts and vascular cells (Frangogiannis, 2008). 
The rigid scar, which does not contribute to the synchronous 
beating of the heart, leads to cardiac dilation, cardiac hypertro-
phy, and eventual cardiac failure (Pfeffer and Braunwald, 1990; 
Dzau et al., 2006; Jourdan-Lesaux et al., 2010; Fraccarollo et al., 
2012; Kempf et al., 2012).
Current Treatments for Myocardial 
infarction
The primary goal in treating acute MI is to restore blood flow 
in an attempt to minimize the size of the infarct and decrease 
the amount of cellular trauma to cardiac tissue. Current medi-
cal practise generally consists of a combination of surgical or 
pharmacological techniques (Wijns et al., 2010; Steg et al., 2012). 
Primary surgical techniques utilized to reperfuse the system are 
the implantation of stents and coronary artery bypass surgery 
(Wijns et  al., 2010). A variety of pharmacological agents are 
also used either to avoid or complement surgical techniques. 
Thrombolytics are an option to circumvent potentially invasive 
surgical methods if successful as they are designed to break up 
clots in order to restore blood flow (Antman et al., 2004). Other 
therapies include the use of vasodilators and blood thinners in 
order to promote blood flow and reduce the risk of further clot 
formation (Antman et  al., 2004; Wijns et  al., 2010; Steg et  al., 
2012). All these therapeutic techniques aim to restore cardiac 
perfusion while further medication is prescribed in order to 
manage patient symptoms and prevent further damage to the 
structural components of the heart. Despite the success of these 
treatments in saving and improving the quality of life of patients, 
they do not address the underlying cause of the disease and do 
not replace the tissue that is lost. Since the heart has a very 
low capacity for regeneration, new treatments are required in 
order to grow new tissue and heal the heart at the cellular and 
molecular level.
Use of Biomaterials to Treat Mi
Over the last decade, there are has been considerable research 
dedicated to the development of biomaterials, both synthetic 
and natural (see Table 1 for list of abbreviations), to aid in the 
healing process post-MI (Suuronen et al., 2006, 2009; Jourdan-
Lesaux et  al., 2010; Rane and Christman, 2011; Kuraitis et  al., 
2012; Ahmadi et al., 2014a). Biomaterials can take many forms 
from injectable hydrogels to solid patches and can serve a variety 
of purposes. A left ventricular restraint is a device that is surgi-
cally implanted on the outer wall of the heart in order to provide 
increased mechanical support to the weakened ventricle of the 
infarcted heart (Rane and Christman, 2011). Cardiac patches, 
which can be created in the lab and sutured or applied to the 
surface of the tissue at the site of myocardial injury, have also been 
employed. These integrate with the host tissue and can be used 
to deliver therapeutics such as drugs, growth factors, or small 
molecules (Rane and Christman, 2011). Recently, there has been 
an increasing amount of research into injectable hydrogels that 
can be delivered directly into the cardiac tissue. Although much 
research has been performed in the development of biomaterials 
to enhance cell transplantation therapies, it is increasingly evident 
FiGURe 1 | evolution of the infarcted myocardium. MI results in the activation of a multiphase healing process, involving three overlapping phases: the 
inflammatory, proliferation, and maturation phases. This repair process prevents ventricular rupture, but it is insufficient to protect the myocardium from massive 
tissue loss and adverse remodeling.
3
Lister et al. Cell–Material Interactions in MI Heart
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org July 2016 | Volume 4 | Article 62
that biomaterials can also be effective on their own without the 
cells, which is the focus of this review. Thus far, various biomateri-
als have been shown to improve left ventricular ejection fraction 
(LVEF), reduce infarct size and scarring, and enhance tissue 
viability, angiogenesis, and cardiomyogenesis. It is clear that bio-
materials are capable of improving cardiac repair at a cellular level 
rather than just controlling the effects of deteriorating function 
(Venugopal et al., 2012; Jalil and Seliktar, 2015; Pascual-Gil et al., 
2015; Wang and Christman, 2015).
Post-MI, the composition of the cardiac ECM undergoes 
considerable change as it is remodeled through the inflammatory, 
proliferative, and maturation phases of ischemic injury (Li et al., 
2014). Since a cell’s function is controlled, in part, by interac-
tions with the ECM environment, the cardiac ECM changes that 
occur post-MI can significantly affect the reparative response of 
the cells in the heart (Dobaczewski et  al., 2011; Bayomy et  al., 
2012; Fan et al., 2014) (Table 2). Given the wide variety and tun-
ability of available biomaterials, the opportunity exists to design 
biomaterials that can specifically target and enhance the repair 
function of different cell types in the MI heart (Figure 2). The goal 
of this review is to outline the role of four main cell types in the 
infarcted heart (macrophages, fibroblasts, endothelial cells, and 
cardiomyocytes) and provide some examples of how biomaterials 
have been used to alter the function of these cells to promote 
cardiac repair post-MI.
CARDiOMYOCYTeS
Cardiomyocytes in the Healthy 
Myocardium
From before birth until death, the heart is continuously work-
ing to contract and perfuse the body with oxygenated blood. 
To support the very high metabolic activity of the heart, the 
myocardium is densely vascularized to ensure adequate oxygen 
metabolism in order to avoid metabolic stress and the formation 
of reactive oxygen species (ROS). Electrical communication 
between cardiomyocytes occurs via gap junctions and is critical 
for regulating synchronous muscle contractions and pumping 
function. The myocardium also relies on the ECM for mechanical 
support. During diastole, collagen in the ECM passively provides 
stiffness to prevent temporal dilation while during systole it is 
able to transduce force across the myocardium (Leonard et al., 
2012; Winslow et al., 2015). In addition, the interaction of cardio-
myocytes with the ECM promotes survival and function (Kresh 
and Chopra, 2011; Okada et al., 2013).
Function of Cardiomyocytes Post-Mi
Due to the high metabolic requirements of cardiomyocytes, oxy-
gen is one of the most important factors in heart function. During 
infarction, the oxygen supply is blocked or reduced to a point 
where the oxygen demand exceeds the supply causing excessive 
FiGURe 2 | Timing considerations for the application of biomaterial therapies. This schematic summarizes the timeline of post-MI processes and identifies 
some associated potential cellular targets for biomaterial therapy.
TABLe 2 | Cell responses and functional changes post-Mi.
Cardiomyocytes Macrophages Fibroblasts endothelial Cells
Cellular  
dysfunction 
 – Cell death
 – Minimal regeneration
 – M1 invasion
 – Inflammation
 – Myofibroblast phenotype
 – Extended activity
 – Apoptosis and necrosis
 – ROS production
Adverse  
function
 – ↓Contractility
 – Ventricular thinning 
 – Excessive MMP activity
 – Pro-nectrotic signaling
 – ECM deposition
 – Cardiac hypertrophy
 – Stiffening 
 – ↓ Cardiac perfusion
 – Sustained hypoxia 
The response of different cell types after myocardial infarction and the resultant negative outcome of these responses that may contribute to heart failure development.
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amounts of cardiomyocyte death. This cell death leads to a thin-
ning of the ventricular wall in the affected area making it suscep-
tible to rupture. In order to prevent ventricular rupture, the dead 
muscle is replaced with a rigid fibrous scar that does little more 
than provide mechanical support. As this scar does not provide 
much utility in the form of contractility, cardiac function contin-
ues to deteriorate over time. Although cardiomyocyte turnover 
in the adult myocardium has been shown to occur, these cells 
lack the ability to regenerate a sufficient amount of new muscle 
to heal the infarcted heart (Zhang et al., 2015; Awada et al., 2016). 
Therefore, there is an opportunity for the use of biomaterials to 
help boost the regenerative capacity of cardiomyocytes through 
the modulation of proliferation, remodeling, and survival.
Biomaterials that Alter Post-Mi 
Remodeling and Cardiomyocyte 
Properties
This section will highlight some studies that have reported on 
biomaterial treatments (± growth factors) with positive effects on 
infarct evolution and cardiomyocyte function.
Ligand and Cytokine-Loaded Biomaterials for 
Favorable Remodeling and Cardiomyocyte Function
Biomaterials can be supplemented with growth factors with the 
aim of preventing adverse ventricular remodeling and promot-
ing cardiomyocyte survival and function. There are numerous 
examples of this strategy, of which some will be highlighted 
in the following sections. In one study, Cohen et  al. (2014) 
encapsulated neuregulin-1β (NRG), a member of the epidermal 
growth factor family, into a hydroxyethyl methacrylate hyalu-
ronic acid (HEMA-HA) biomaterial. Sustained release of NRG 
from the biomaterial was maintained for 14 days in vitro as the 
biomaterial degraded. In vivo, MI hearts treated with NRG/
HEMA-HA showed increased NRG content within cardio-
myocytes and reduced caspase-3 expression compared to hearts 
treated with NRG alone, suggesting that the sustained release of 
NRG can improve cellular uptake and confer a cardioprotective 
effect. After 2  weeks, animals treated with NRG/HEMA-HA 
had significantly improved morphology (LV area) and function 
(LVEF) compared to the other treatment groups. Similar work 
from this group examined the effect of their HEMA-HA bio-
material conjugated with engineered stromal cell-derived factor 
5Lister et al. Cell–Material Interactions in MI Heart
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1-α (ESA) (Macarthur et al., 2013). The issue of the chemokine’s 
short half-life was addressed by the encapsulation process – ESA 
could be released and maintain its bioactivity for greater than 
28 days when loaded into the HEMA-HA hydrogel. MI hearts 
treated with the ESA/HEMA-HA hydrogel had reduced scar size 
and LV dilation, and increased LVEF compared to the controls. 
It has been shown that an imbalance between proteolytic matrix 
metalloproteinases (MMPs) and tissue inhibitors of MMPs 
(TIMPs) contributes to adverse cardiac remodeling post-MI 
(Kassiri et al., 2009). As a strategy to correct this issue, recombi-
nant TIMP-3 (rTIMP-3) was locally administered into infarcted 
porcine hearts using a hyaluronic acid hydrogel. There was a 
concentration-dependent inhibition of MMPs followed by a 
decrease in left ventricular end diastolic dimension (LVEDd) 
and an increase in LVEF compared to hydrogel-only and saline 
treated controls (Eckhouse et al., 2014). After 2 weeks, infarct 
expansion was decreased, and interstitial MMP levels were 
reduced in rTIMP + hydrogel treated animals compared to all 
controls. This demonstrates that regulation of MMP/TIMP-
mediated remodeling can be a target for preserving cardiac 
morphology and function post-MI.
Several studies have investigated hydrogels for the release of 
growth factors that can improve cardiomyocyte survival. For 
example, an injectable poly (lacto-co-glycolic acid) (PLGA) 
nanoparticle was used to bind and deliver insulin-like growth 
factor-1 (IGF-1), a cytokine that can promote cardiomyocyte 
proliferation and survival (Chang et  al., 2013). IGF-1 loaded 
PLGA nanoparticles were injected immediately post-MI result-
ing in increased phosphorylation of the cardioprotective pro-
tein Akt and a reduction in the number of TUNEL+ apoptotic 
cardiomyocytes at 24-h post-injection, compared to injection of 
IGF-1 alone. After 3 weeks, hearts which received injection of 
IGF-1 nanoparticles had reduced scar size and superior LVEF 
compared to controls. It appears that the biomaterial treatment 
in conjunction with sustained IGF-1 release provided early 
cardioprotective effects leading to reduced remodeling and 
enhanced function of the infarcted heart. Another study uti-
lized a biomaterial derived from porcine ECM in combination 
with an engineered hepatocyte growth factor (HGF) fragment 
(Sonnenberg et al., 2015). The ECM + HGF hydrogel was able 
to protect cardiomyocytes from serum starvation and reduce 
fibrotic markers in explanted cardiac cell cultures. In vivo, 
treatment with ECM +  HGF hydrogel attenuated ventricular 
remodeling and improved function of the MI heart compared to 
all control groups. Ruvinov et al. (2011) designed a dual growth 
factor delivery alginate gel that could sequentially release IGF-1 
followed by HGF upon injection. In a rat model for acute MI, 
treatment with the gel containing both growth factors led to 
less cell apoptosis, reduced scar size, and less adverse remod-
eling compared to those that received growth factors in saline, 
the biomaterial without growth factors or the saline control. 
Notably, Ki-67 staining suggested that more cardiomyocytes 
re-entered the cell cycle and proliferated in the myocardium 
of rats treated with the IGF-1/HGF gel compared to the other 
treatment groups. In another dual delivery approach for treat-
ing MI, IGF-1 and 6-Bromoinirubin-3-oxime (BIO) were pack-
aged into gelatin nanoparticles and complexed to an alginate 
hydrogel (Fang et al., 2015). This was successful at prolonging 
the stability of the nanoparticles, as their presence was still 
observed by immunofluorescence at 45  days post-injection 
compared to nanoparticles alone, which were not detectable 
beyond 10 days. The injection of IGF-1 in biomaterial, BIO in 
biomaterial, or IGF-1 + BIO in biomaterial all lead to an increase 
in the function of the MI rat heart. Hematoxylin and eosin, and 
cardiac troponin-T staining revealed that a greater number 
of cardiomyocytes were present in the infarct area of animals 
treated with the IGF-1 + BIO biomaterial compared to the other 
treatment groups. Staining for proliferating cell nuclear antigen 
(PCNA) revealed that the combined IGF-1  +  BIO therapy 
also lead to more cardiomyocyte proliferation. Another group 
co-delivered fibroblast growth factor-1 (FGF-1) and NRG to 
treat the MI heart by loading them into poly (lacto-co-glycolic 
acid) microparticles, and observed that this treatment reduced 
infarct size and increased scar thickness leading to superior 
mechanical properties of the recovering heart (Formiga et al., 
2014). Furthermore, decreased fibrosis and apoptosis of cardio-
myocytes was observed, and there was a trend for an increase 
in the number of Ki67+ (proliferating) cardiomyocytes with 
FGF-1/NRG microparticle treatment compared to unloaded 
microparticles.
The incorporation of specific ligands that are involved in 
regulating pro-survival pathways is another attractive target for 
enhancing the ability of a biomaterial to improve cardiomyocyte 
viability and function post-MI. In one study, the angiopoetin-
1-derived peptide QHREDGS, capable of binding integrins, 
was added to a hydrogel composed of collagen (type of collagen 
not specified) and the polysaccharide chitosan (termed the 
QHG213H gel) (Reis et al., 2015). Hearts treated with QHG213H 
had reduced scar size and improved function compared to the 
control gel (no QHREDGS) and non-injected animals, which 
persisted to the 6-week time point. In terms of cell death and 
cardiomyocyte viability, QHG213H treatment resulted in 
fewer TUNEL+ apoptotic cells and significantly more cardiac 
troponin-T+ cardiomyocytes compared to controls; there was 
also an increase in the expression of anti-apoptotic markers and 
decreased pro-apoptotic gene expression. These data suggest 
that QHG213H treatment can preserve cardiomyocytes post-MI 
leading to cardiac functional and morphological improvements. 
Collectively, the studies discussed above demonstrate several 
growth factor and ligand biomaterial strategies that can improve 
post-MI repair through enhanced cardiomyocyte survival and/
or proliferation.
Another target for biomaterial therapy in the heart is the resi-
dent population of stem/progenitor cells, which have the capacity 
to differentiate into new cardiac cells, including cardiomyocytes 
(Mayfield et al., 2014). In a study by Boopathy et al. (2014), the 
responsiveness of cardiac progenitor cells (CPCs) to Notch1 
signaling was exploited in the design of a biomaterial therapy for 
treating the infarcted heart. In order to stimulate Notch1 activation 
in CPCs, jagged-1 (a Notch1 ligand) was incorporated at varying 
concentrations to the self-assembling peptide RADA16-II [1RJ 
or 2 RJ (concentration dependent)], which forms nanofibers at 
physiological temperatures. After 48 h of culture, CPCs on 1RJ 
hydrogels had greater expression of Hey1, a downstream target of 
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Notch1, as well as increased expression of endothelial genes Flt1 
and vWF, and smooth muscle genes Tagln and Acta2 compared to 
control gels. In comparison, CPCs cultured on 2RJ gels also had 
increased Hey1 expression, but also greater expression of cardiac 
genes nkx2.5, mef2c, and gata4, which was not observed with 1RJ 
gel cultures. Moreover, CPCs cultured on the 2RJ hydrogel for 
24 h exhibited more proliferation than all controls, as determined 
by 5-ethynyl-2′-deoxyuridine (EdU) incorporation, indicating a 
role for Notch1 activation in the CPC proliferation induced with 
this hydrogel. In vivo, CPCs + hydrogels were tested in a rat MI 
model. Use of the 2RJ hydrogel for cell delivery resulted in greater 
CPC retention after 7 days, which was accompanied by improved 
cardiac function. There was also a trend for increased contractil-
ity in animals treated with 2RJ gels and a significant decrease in 
fibrosis compared to controls. In a similar approach, jagged-1 
was crosslinked to fibrin nanoparticles in order to study Notch1 
activation on human embryonic stem cells (hESCs) and CPCs. 
When cultured on the biomaterial, hESCs had increased Hey1 
expression compared to culture on the nanoparticles alone, indi-
cating a jagged-1 mediated activation of Notch1 signaling. When 
CPCs were plated on the jagged-1 nanoparticles, there were more 
cells expressing cardiac troponin-T and the cardiac transcription 
factor TMNT2, as well as greater formation of spontaneous beat-
ing sheets of cardiomyocytes (Tung et  al., 2014). When hESCs 
were differentiated into cardiomyocytes and then plated on the 
jagged-1 biomaterial, greater cardiomyocyte proliferation was 
observed.
These studies demonstrate different promising growth factor- 
or ligand-enhanced biomaterial strategies that can (1) reduce 
cardiomyocyte loss, (2) stimulate cardiomyocyte proliferation 
within the infarct, and/or (3) promote the differentiation and/
or proliferation of cardiomyocytes from stem/progenitor cell 
sources, ultimately leading to less adverse remodeling and 
improved cardiac function post-MI.
Biomaterial Therapy Alone for Favorable Remodeling 
and Cardiomyocyte Function
Biomaterials designed as meshes or injectable materials from 
a wide variety of natural proteins and/or synthetic polymers 
can also be effective treatments for MI on their own without 
additional growth factors or ligands. In one of the earliest of 
such studies, calcium cross-linked alginate was injected into the 
infarcted myocardium leading to a 53% increase in scar thick-
ness compared to controls, and it improved cardiac function in a 
dose-dependent manner (Leor et al., 2009). In a separate study, it 
was also found that the alginate gel increased scar thickness and 
cardiac function (fractional area change, LVEF) more so than 
neonatal cardiomyocyte transplantation (Landa et  al., 2008). 
More recently, alginate was crosslinked with chitosan and injected 
into a rat model of MI (Deng et al., 2015). The myocardium of 
rats treated with the chitosan–alginate gel had fewer apoptotic 
nuclei and less cell death compared to chitosan- or alginate-only 
treated animals. Notably, greater recruitment of endogenous 
ckit+ CPCs and more Ki67+ proliferating cardiomyocytes were 
observed with the chitosan–alginate treatment compared to 
controls, suggesting that more regeneration was stimulated with 
the chitosan–alginate gel. In addition to increased proliferation 
and recruitment, chitosan–alginate-treated animals had less 
adverse ventricular remodeling and superior cardiac function 
compared to controls. Chitosan has also demonstrated positive 
results when coupled with the conductive polymer polypyrrole 
(PPy) (Mihic et al., 2015). In vitro, it was shown that culture on 
a PPy–chitosan hydrogel could increase the rate of Ca2+ signal 
conduction in isolated neonatal cardiomyocytes compared to 
chitosan alone or the uncoated tissue culture plate. In vivo, 
rat MI hearts treated with the PPy–chitosan gel had increased 
transverse activation velocity and more efficient contractions as 
determined by the reduced QRS interval compared to controls. 
PPy–chitosan-treated animals also had reduced scar size and 
improved cardiac function compared to those treated with saline 
or chitosan alone. These results suggest that a material that 
enhances biological conduction can promote greater functional 
recovery post-MI than a non-conductive material.
Collagen, the most abundant ECM protein in the heart, is 
widely used in cardiac tissue engineering applications. Type 1 
collagen-based biomaterials delivered as patches or injectable 
hydrogels have demonstrated the ability to reduce scar size and 
adverse remodeling (Figure 3) and to improve function of the 
MI heart (Serpooshan et  al., 2013; Ahmadi et  al., 2014a; Xu 
et al., 2014; Blackburn et al., 2015). In one study, small intestinal 
submucosal ECM (SIS-ECM), which is composed primarily of 
various collagens (type 1 most abundantly), was injected with and 
without circulating angiogenic cells (CACs) into a mouse model 
of MI (Toeg et al., 2013). Treatment with SIS-ECM alone and with 
SIS-ECM + CACs both lead to greater LV posterior wall thickness 
and reduced infarct size compared to PBS injected control ani-
mals. Newly formed cardiomyocytes and/or cardiac progenitor 
cells were observed in animals treated with SIS-ECM both with 
and without CACs. In other work, cardiac ECM, derived from 
the decellularization of porcine myocardium, has been shown to 
attenuate adverse remodeling and the deterioration of adverse 
cardiac function of the MI heart in both rats and pigs (Singelyn 
et al., 2012; Seif-Naraghi et al., 2013). In pigs, there was visible 
muscle retention in the endocardium of cardiac ECM-treated 
animals with neovascularization observed below these beds of 
cardiomyocytes (Seif-Naraghi et al., 2013).
Hyaluronic acid (HA)-based biomaterials have also shown 
promise in preserving ventricular morphology and cardiac 
function post-MI. For example, MI pig hearts treated with a 
degradable HA hydrogel (delivered 30 min after induction of MI) 
had decreased LV end systolic and diastolic volumes at 1-week 
post-treatment compared to saline controls, indicating initial 
preservation of function (Dorsey et  al., 2015). Furthermore, 
there was a trend of increased function (LVEF) in HA-treated 
animals at all time points, which reached significance at 8 weeks 
post-MI. This increased function may be due, in part, to the 
preservation of ventricular thickness and decreased LV volumes 
conferred by the biomaterial at 4, 8, and 12  weeks post-MI 
compared to saline. The same group has also reported on the 
use of a HEMA-HA hydrogel containing PLGA microspheres 
as a bulking agent for treating the MI heart. It was found that 
injection of a fast-degrading HEMA-HA hydrogel containing 
microspheres led to increased thickness of the apical infarct 
area compared to HEMA-HA alone and infarct control (Tous 
FiGURe 3 | Tissue sections of mouse Mi hearts injected with PBS (left) or type 1 collagen biomaterial (right). Note the dilation and thinning of the 
collagen scar (blue tissue) in the PBS-treated heart, compared to the preservation of wall thickness and viable muscle (red) in the collagen biomaterial-treated heart.
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et  al., 2012). This thickening was accompanied by greater cell 
infiltration surrounding the PLGA microspheres and an increase 
in blood vessel density.
Biomaterials for treating MI have also been developed 
from a variety of synthetic polymers. For example, poly(ϵ-
caprolacetone)-2-HEMA and poly(N-isopropylacrylamide) 
(PNIPAAm) were added to a biodegradable dextran chain to 
yield a Dex-PCL-HEMA/PNIPAAm hydrogel (Wang et  al., 
2009). Upon injection to the MI heart, this material formed a gel 
rapidly and reduced scar size while increasing ventricular wall 
thickness and preventing LV dilation compared to PBS injected 
controls. Hydrogels based on PEG, a commonly used synthetic 
polymer, have also been shown to have therapeutic potential for 
the treatment of MI. One study evaluated the effect of timing of 
delivery on its therapeutic efficacy (Kadner et al., 2012). It was 
shown that injection of the hydrogel at 1-week post-MI led to 
greater ventricular wall thickness compared to animals that were 
treated with the PEG hydrogel immediately after induction of MI 
(day 0). This observation was attributed to more rapid degrada-
tion of the material in the acute inflammatory environment when 
injected at the earlier time-point thus reducing its effectiveness as 
a bulking agent.
Altering the chemical composition of a biomaterial and 
physical characteristics such as stiffness can lead to changes in 
outcomes. This is demonstrated by a study in which hydrogels 
composed of PEG-fibrinogen (PF) were chemically modified to 
yield materials of different stiffness (Plotkin et al., 2014). Injection 
of the biomaterial to the MI heart led to an increase in LVEF com-
pared to untreated controls with trends indicating that stiffer PF 
hydrogels conferred superior cardiac function. The stiffer PF was 
also better able to attenuate scar expansion and limit ventricular 
remodeling compared to the weaker PF. It should be noted that 
a material that is too stiff may limit the differentiation of mature 
cardiomyocytes or promote osteogenic differentiation (Engler 
et al., 2006; Forte et al., 2012). Therefore, physical properties of 
biomaterials can play a role in treatment outcome, and this may 
be dependent on the type of material, as well as the manner of 
its delivery.
Increasingly, researchers are investigating the use of bioma-
terials to assist in the differentiation and therapeutic application 
of cardiomyocytes derived from embryonic stem cells (ESC), 
induced pluripotent stem cells (iPSC), and cardiac stem cells 
(CSC). The issue of maturing the stem cell-derived cardiomyo-
cyte is important and the use of biomaterials presents an attrac-
tive approach to address this. For example, in one study, a 3D 
type 1 collagen scaffold was developed for the co-culture of bone 
marrow stromal cells (BMSCs) and embryonic cardiac myocytes 
(Valarmathi et  al., 2010). This culture system was able to yield 
maturing cardiomyocytes with emerging Z lines and sarcomeric 
fibers. An innovative engineering technique combined 3D cell 
culture with electrical stimulation to create biowires (Nunes et al., 
2013). In this method, human iPSC were differentiated into naive 
cardiomyocytes and seeded on the biowire. Cells were either not 
stimulated or stimulated with electricity at high or low frequen-
cies. The electrical stimulation resulted in cells adopting a rod-like 
phenotype (as opposed to round), indicative of cardiomyocyte 
maturation. Along with an increase in cardiomyocyte hypertro-
phy, high stimulation resulted in cells with organized sarcomeric 
banding and aligned Z discs. There was also a decrease in the 
expression of fetal genes and greater electrical coupling between 
cells, further confirming maturation. Another group created bio-
materials using varying amounts of PEG, PCL, and carboxylated 
PCL (cPCL) in order to optimize a substrate for the maturation 
of iPSC-derived cardiomyocytes. Of the four materials tested, 
plating iPSC-derived cardiomyocytes on a mixture containing 
4%PEG-96%PCL resulted in the greatest mitochondrial activity 
and strongest contractile forces generated (Chun et  al., 2015). 
This was accompanied by an increase in the expression of cardiac 
genes including myosin light chain-2v and intermediate filaments 
known to mediate interactions with integrins. Most importantly, 
cardiomyocytes cultured on 4%PEG-96%PCL transitioned from 
expressing the fetal slow skeletal TnI (ssTnI) gene to expressing 
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post-natal cardiac troponin-T, a hallmark of cardiomyocyte 
development and maturation. Depending on the particular strat-
egy, the maturation of cardiomyocytes derived from ESC or iPSC 
may be a necessity before these cells can be viably transplanted.
Another application of biomaterials is in the generation and/
or expansion of CSCs for therapy. For example, one group has 
reported on a 3D gel composed of fibrinogen and thrombin 
that was used to encapsulate and culture atrial cardiac tissue 
fragments in vitro (Kim et al., 2015). The biomaterial provided 
an ideal environment for the generation of CSCs as stromal cells 
appeared from the fragments after only 1 day in culture. The CSCs 
were viable and proliferating as determined by the incorporation 
of BrdU. It was also determined that the biomaterial enhanced 
cardiac integrin β1 signaling in CSCs compared to those cultured 
without the biomaterial. A system such as this may be capable of 
providing CSCs for further research and clinical use.
The volatile post-MI environment results in apoptosis and 
necrosis, the massive loss of cardiomyocytes, and adverse 
ventricular remodeling leading to cardiac dysfunction. There 
are numerous different strategies being investigated that make 
use of biomaterials to stimulate cardiomyocyte differentiation, 
proliferation and survival, providing hope that regeneration of 
cardiac muscle for treating MI may be possible.
MACROPHAGeS
Role of Native Macrophages
Macrophages are of the most abundant immune cells in the body. 
All macrophages, regardless of their resident location, participate 
in the detection of pathogens and damaged tissue, as well as 
the clearance of cellular debris (Pinto et al., 2014b). This occurs 
through macropinocytosis, a process involving a variety of pat-
tern recognition receptors, toll-like receptor mediated identifica-
tion of antigens, and the secretion of chemical factors (Lim and 
Gleeson, 2011). It is important to note that macrophages can 
be classified into two broad categories: M1 and M2 phenotype 
macrophages. Although this is a simplification (Frangogiannis, 
2012b), there are subsets within each category (Gordon, 2003; 
Mantovani et al., 2004). M1 macrophages are considered to be 
pro-inflammatory and mediate the initial stages of inflammation 
after injury/insult; while M2 macrophages have an opposing 
function, as they are anti-inflammatory, and promote wound 
healing and regenerative processes such as angiogenesis to help 
return the tissue to its natural state (Gordon, 2003; Mantovani 
et al., 2004; Nahrendorf et al., 2007, 2010; Frantz and Nahrendorf, 
2014; Zhang and Wang, 2014). The heart has its own resident 
macrophages known as cardiac tissue macrophages (cTMs). The 
cTMs differ from many other macrophages as they display an 
alternatively active, M2-like phenotype (Pinto et al., 2012). cTMs 
interact with other cardiac cell types and play an important role 
in cardiac homeostasis. It has been shown that cTMs are involved 
in capillarization of the myocardium, which may be achieved 
through neuropilin1 (NRP1) signaling and direct interaction 
with endothelial tip cells to promote anastomosis (Fantin et al., 
2010). cMTs also play a role in controlling age-dependent fibrosis, 
particularly at the epicardial level (Biernacka and Frangogiannis, 
2011; Pinto et  al., 2014a). Maintenance of the epicardium is 
critical, as it contains multi-potent progenitor cells that have 
the ability to differentiate into endothelial cells, fibroblasts, and 
smooth muscle cells in the event of cardiac injury (Smart et al., 
2007; Chong et al., 2011).
Evidence continues to accumulate demonstrating the impor-
tance of resident macrophages in maintaining the optimal cardiac 
environment. Understanding how macrophage dysfunction can 
lead to a variety of pathophysiological conditions is likely to 
improve therapies for treating the diseased heart.
Macrophages during Myocardial infarction
Macrophages play a vital role in the healing of cardiac tissue after 
infarction. It is important to remember that macrophages are 
a plastic cell with two main phenotypes (M1 and M2) that are 
derived from the differentiation of monocytes (Gordon, 2003; 
Mantovani et al., 2004; Zhang and Wang, 2014). The inflamma-
tory response after MI is initiated by the release of cytokines 
from injured/dying cardiomyocytes, which stimulates the 
recruitment of neutrophils and monocytes (Sutton and Sharpe, 
2015). Neutrophils and monocytes are among the first cell popu-
lations recruited to the infarct area post-MI, arriving within an 
hour and persisting in the myocardium for several days (Jung 
et al., 2013). The sustained inflammatory environment in acute 
MI causes the release of macrophage colony-stimulating factor 
(M-CSF) leading to the phenotypic transition of monocyte to 
macrophage (Frangogiannis et al., 2003). The polarization state 
of the macrophage (M1 vs. M2) depends on additional stimuli 
received from the cell’s environment and determines the mode 
of action of that particular cell (Mantovani et  al., 2004). M1 
macrophages are known to be pro-inflammatory and are found 
in cardiac tissue soon after MI. This pro-inflammatory phase is 
necessary to promote the removal of debris and to initiate healing 
from other immune cells. M2 macrophages, on the other hand, 
oppose the action of the M1 as they are anti-inflammatory and 
pro-wound healing (Nahrendorf et al., 2007, 2010; Zhang and 
Wang, 2014). M2 macrophages are found in significant numbers 
later in the infarct healing process, at approximately 7  days 
post-MI. M2 macrophages are associated with infarct healing, 
and a shift toward an increased M2:M1 ratio is beneficial for the 
resolution of the inflammatory state and enhancement of angio-
genesis and decreased scar size (Harel-Adar et al., 2011). There 
are several sources for the recruited macrophages. As discussed 
previously, there is a resident population of macrophages within 
the heart tissue, but during MI, this population can become 
quickly exhausted. Cytokine signaling from the injured myocar-
dium also mobilizes additional monocytes/macrophages from 
two other primary resources. In the bone marrow, hematopoietic 
stem cells are signaled through specific adhesion molecules to 
initiate production of mononuclear cell types needed for repair 
(Ehninger and Trumpp, 2011; Lo Celso and Scadden, 2011), and 
monocytes are stimulated to be released and home to the infarct 
area where they differentiate into macrophages upon arrival 
(Dewald, 2005). There also exists a reservoir of monocytes 
within the spleen, which are mobilized post-MI and contribute 
significantly to the macrophage population found during the 
MI healing process (Swirski et  al., 2009). Biomaterial therapy 
may be an attractive strategy to regulate macrophage function 
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in the infarcted myocardium for promoting improved repair/
regeneration.
effect of Biomaterials on Macrophages
Being immune cells, macrophages are very sensitive to their 
environment. Therefore, biomaterials have the potential to 
vastly alter macrophage function and remodeling in the post-MI 
heart. Biomaterials can be designed with different compositions 
and properties in order to regulate macrophage polarization, 
proliferation, and remodeling, and several examples of this are 
discussed in the following section.
Several studies have investigated the effect that biomaterial 
composition can have on macrophage polarization. In one study, 
monocytes isolated from healthy human donors were cultured on 
several different biomaterials for 3 days prior to RNA isolation 
and qPCR for markers of polarization. Cells cultured on either a 
Parietex™ composite or polyethylene terephthalate yielded a high 
M1:M2 index indicating greater M1 polarization, whereas the 
culture of monocytes on polypropylene had the opposite effect: 
greater M2 polarization (Grotenhuis et al., 2013). This shows that 
macrophage polarization can be differentially regulated depend-
ing on the biomaterial administered. In another study, an in vivo 
comparison was made between a natural scaffold derived from 
porcine small intestinal submucosa (SIS), and a crosslinked ver-
sion of SIS, known as a CuffPatch (CDI-SIS) (Badylak et al., 2008). 
In the SIS material, there was a strong mononuclear cell response 
at 1, 2, and 4 weeks after graft implantation, which was determined 
to be predominantly CD163+ M2 macrophages. Throughout the 
observation period, there continued to be a M2 response, and 
at the end of 16  weeks, the surgical area was characterized by 
organized skeletal muscle and collagenous connective tissue. 
Conversely, the crosslinked CDI-SIS patch elicited the recruit-
ment of an equal number of M1 and M2 macrophages at 1 and 
2 weeks, with the M1 phenotype predominating in later weeks, 
and remaining at the border of the patch rather than infiltrating 
into the interior. This demonstrates the potential sensitivity of 
macrophages to a biomaterial, as a single change to SIS resulted 
in drastically different cell responses. Other work has aimed to 
identify polarization, as well as subsequent localization, of differ-
ent cell colonies in response to a variety of different biomaterial 
patches. In the biomaterials that predominantly stimulated M1 
polarization, clusters of M1 macrophages were observed around 
the border of the material, while the few M2 macrophages that 
were present had infiltrated the material’s center and contributed 
to constructive remodeling (Brown et al., 2012). Of the bioma-
terials tested, two were successful at polarizing the majority of 
the cells to an M2 phenotype: the Surgisis® eight-layer porcine 
SIS mesh and the MatriStem® four-layer porcine urinary bladder 
scaffold. Implantation with either of these two biomaterials led to 
dense M2 cell infiltration in the center of the scaffolds with more 
organized tissue formation.
Studies have also focused on how fiber diameter and pore size 
in a biomaterial can alter macrophage polarization and function. 
For example, undifferentiated macrophages (M0) were cultured 
in vitro on PDO scaffold materials, generated by electrospinning 
PDO at increasing concentrations to yield increasingly thicker 
fibers with larger pores. Notably, greater expression of the M2 
marker arginase, and reduced expression of the M1 marker iNOS, 
was observed on scaffolds with larger fibers and pore sizes, sug-
gesting that larger fiber and pore size promote the differentiation 
of M2 macrophages (Garg et al., 2013). In terms of functionality, 
the M2-differentiated macrophages were more potent in promot-
ing capillary-like formation in an in vitro angiogenesis assay com-
pared to M1-differentiated macrophages. Similar findings were 
reported by a group using electrospun poly(ϵ-caprolacetone) 
(PCL) vascular grafts: in  vitro, macrophages cultured on PCL 
with large pores underwent significantly greater M2 polariza-
tion compared to those cultured on small pore grafts, which 
yielded more M1 phenotype cells (Wang et  al., 2014). In vivo, 
PCL grafts were transplanted into the abdominal aorta, and 
the macroporous grafts promoted enhanced M2 macrophage 
infiltration subsequently leading to further cellular infiltration 
and vascularization. After 100 days, there was functional smooth 
muscle receptive to hormonal control and complete endothelium 
coverage. Although neither of the above mentioned studies were 
applied in a cardiac setting, both provide insights into engineer-
ing techniques that could be applied to regulate macrophage 
phenotype and infiltration in an MI model.
Research groups have also characterized the response of 
macrophages on cellular vs. acellular grafts. One study using a 
rat abdominal defect model compared the effects of an autolo-
gous cellular and acellular patch or a cellular and acellular patch 
derived from the bladder of a xenogeneic pig (Brown et al., 2009). 
In both the autologous and xenogeneic cellular grafts, it was 
found that M1 polarization predominated throughout the 28-day 
sampling period as determined by immunohistochemical find-
ings. Conversely, both the types of acellular patches promoted 
predominately M2 polarization. The increased M2 polarization 
was associated with more constructive remodeling of the injured 
area while the cellular grafts with M1 dominance showed deposi-
tion of dense connective tissue and scar formation.
It is evident that macrophages are highly responsive to their 
interactions with biomaterials. Macrophage phenotype and func-
tion play a significant role in the remodeling of the post-MI heart; 
therefore, how a biomaterial affects macrophages may ultimately 
decide the overall success of a biomaterial therapy. While most 
studies focus primarily on the polarization of macrophage pheno-
type in response to the biomaterial, it may be equally important 
to understand the remodeling effects that take place after the 
macrophage infiltration. It appears that the M2 macrophage 
phenotype can confer beneficial constructive remodeling in 
damaged tissues. Research has revealed much about macrophage/
biomaterial interactions; however, it will be imperative to test 
biomaterial effects on macrophage polarization and function in 
relevant models of MI, as other models do not fully recapitulate 
the post-MI environment, which may affect both the material and 
the macrophages.
FiBROBLASTS
Function in a Healthy Heart
In a healthy heart, fibroblasts play a relatively minor role com-
pared to other cardiac cells like cardiomyocytes. They function 
in the background as key regulators of ECM and cardiac tissue 
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homeostasis through autocrine and paracrine signaling. Cardiac 
fibroblasts both produce ECM proteins and secrete a variety of 
factors that degrade the ECM [e.g., matrix metalloproteinases 
(MMPs)], making them responsible for the overall maintenance 
of the ECM in cardiac tissue (van Nieuwenhoven and Turner, 
2013). In addition to the production of MMPs, cardiac fibro-
blasts secrete the tissue inhibitors of MMPs (TIMPs), which 
allow them to tightly regulate ECM turnover (Brown et al., 2007; 
Turner et al., 2010). Cardiac fibroblasts also produce a variety 
of matricellular proteins such as connective tissue growth fac-
tors (e.g., CTGF/CCN2), tenascins, and thrombospondins 
(Frangogiannis, 2012a) that do not provide structural support, 
but have a role in controlling cell–matrix interactions and cel-
lular function (Bornstein and Sage, 2002). In response to stress, 
such as MI, fibroblasts are activated and play a key role in the 
resulting cardiac remodeling process.
Dysfunction during Myocardial infarction
The cardiac fibroblast is a plastic cell with at least two distinct 
phenotypes. During MI, environmental cues of stress and ten-
sion are thought to cause the phenotypic change of the fibroblast 
to that of a myofibroblast, which is more responsive and better 
able to infiltrate the infarct zone (van den Borne et  al., 2010; 
van  Nieuwenhoven and Turner, 2013). Myofibroblasts are 
 characterized by the expression of contractile proteins such as 
α-smooth muscle actin (α-SMA), an increased expression of 
focal adhesion proteins (e.g., cadherin), and a change in the 
production of ECM proteins, MMPs and TIMPs (Tomasek et al., 
2002; van den Borne et al., 2010). Following the phase of acute 
inflammation, myofibroblasts migrate and proliferate within the 
infarct area during the proliferative phase post-MI. The role of 
myofibroblasts is to replace the dead or damaged cardiomyocytes 
with a deposition of ECM proteins that creates the infarct scar. 
Initially type III collagen is deposited, which is followed by 
greater production of type I collagen (Cleutjens et  al., 1999). 
Because of the resilient nature of cardiac myofibroblasts, many 
remain active in the infarct area during remodeling/maturation 
of the scar, as well as dispersed throughout the heart actively 
depositing collagen (van den Borne et al., 2010). Although this 
process of interstitium fibrosis is required to prevent perforation 
of the ventricular wall, over time the increased stiffness of the scar 
tissue is detrimental to the heart and leads to conditions such as 
cardiac hypertrophy and cardiomyopathy, and the deterioration 
of cardiac function (Opie et  al., 2006; Schocken et  al., 2008). 
Given the key role of fibroblasts/myofibroblasts in ventricular 
remodeling and stiffening of the myocardium, these cells are an 
attractive target for regulation by biomaterial therapy.
Biomaterials Alter Fibroblast Function 
Post-Mi
Several studies have evaluated the ability of biomaterials to 
modulate fibroblast function with the hope of minimizing or 
preventing adverse remodeling events post-MI. For example, a 
3D polyethylene glycol (PEG) in vitro model was tested for its 
capacity to control fibroblast viability, migration, and function. 
Entrapping the cells within the PEG framework through covalent 
crosslinking and gelation of the material did not appear to harm 
the cells as viability in the range of 90–95% was observed after 
this process (Raeber et al., 2007). It was found that the migration 
of fibroblasts within PEG was significantly reduced in the pres-
ence of MMP inhibitors, indicating that fibroblast migration was 
dependent on MMPs. MMP activity was deemed necessary to 
digest the PEG’s pores of nanoscale size that otherwise restrict the 
passage of cells. In terms of function, fibroblasts were observed to 
form interconnected 3D cellular networks within the PEG hydro-
gel over a period of several weeks, demonstrating their capability 
for long-term survival within the material. Another study aimed 
to measure the effect of varying hydroxyapatite particle size on 
fibroblast proliferation. At all time points, a significantly greater 
number of cells was observed on the hydroxyapatite with larger 
particle size (Sun et al., 1997), suggesting that greater particle size 
provides the cells with more space to proliferate. These studies 
demonstrate that physical space within a material can have an 
effect on cell behavior.
The composition, and more specifically the interactive sites, of 
a biomaterial can also regulate fibroblasts activity. For example, 
in 3D PEG networks, the incorporation of the cell-adhesion 
motif RGD led to significantly increased fibroblast proliferation 
compared to hydrogels without the motif. Proliferation was 
also determined to be associated with biomaterial stiffness, 
independent of RGD or MMP sensitivity of the hydrogel: as 
the elastic modulus (stiffness) of the material was increased, 
fibroblast proliferation significantly decreased over a period of 
21  days (Bott et  al., 2010). This observation in  vitro suggests 
that increased stiffness of the collagenous scar post-MI may be 
a factor contributing to the minimal cellularity of the scar. It may 
be worth directing research toward ways of softening the scar to 
improve its recellularization.
In an in vitro model for blood vessel regeneration, a dual-layer 
composite biomaterial consisting of poly-ϵ-caprolacetone as the 
inner layer and poly-lactic acid as the outer layer was created by 
electrospinning (Vaz et al., 2005). Fibroblasts proliferated along 
the length of the tubular scaffold after 1 week, and after 1 month, 
confluence was achieved and myofibroblasts congregated more 
closely at the surface of the scaffold. Myofibroblasts cultured on 
the tubular scaffold deposited less ECM proteins and glycosa-
minoglycans compared to a control porcine pulmonary valve 
material. Although not tested in the cardiac setting, this suggests 
that the composite biomaterial may have the ability to limit the 
ECM remodeling function of myofibroblasts, which may have 
the potential to decrease cardiac fibrosis post-MI if applied at 
the opportune time (i.e., after the susceptibility to rupture has 
passed). Another group used electrospun silk fibroin nanofib-
ers coated with different ECM proteins to see how fibroblasts 
response would be affected. Fibroblasts were seeded on tissue 
culture polystyrene, silk fibroin, bovine serum albumin, type 1 
collagen-coated silk fibroin, fibronectin-coated silk fibroin, or 
laminin-coated silk fibroin. The cells that adhered to collagen- 
and laminin-coated silk fibroin exhibited a spreading morphol-
ogy characteristic of proliferating fibroblasts more so than the 
cells in the other substrate groups (Min et al., 2004). It is evident 
from the numerous culture studies that materials can be modified 
to differentially regulate the function of fibroblasts.
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While promising results are being generated in  vitro, there 
are many factors present in the post-MI heart in  vivo that are 
not reproduced in the culture models. Therefore, establishing the 
effects of a biomaterial on fibroblast activity and function using 
animal models of MI is critical. One particularly good example of 
this comes from a study in which alginate was modified by cova-
lently adding RGD and YIGSR adhesion domains to provide cell 
adhesion sites. In vitro, fibroblasts displayed strong adhesion to 
the modified biomaterial, which was predicted to enhance the cell 
response in vivo (Tsur-Gang et al., 2009). However, the peptide-
modified materials exhibited reduced therapeutic potential when 
applied in a rat MI model compared to the unmodified alginate. 
No differences were observed in the infiltration of fibroblasts or 
cell proliferation between the different alginate formulations after 
8 weeks. It was postulated that the peptide-modified alginate may 
undergo additional mechanical changes upon injection in  vivo 
that may affect structure and stiffness, thus altering its physical 
support properties as well as its influence on cell function. In 
another study, fibroblasts cultured on a type 1 collagen–chitosan 
hydrogel had less α-SMA expression and less deposition of fibril-
lar collagen than cells cultured on the collagen-only hydrogel 
(Ahmadi et al., 2014b). In vivo, intramyocardial injection of the 
chitosan–collagen material to MI mouse hearts resulted in less 
fibrosis, superior scar thickness, and improved cardiac function 
compared to hearts treated with the collagen only hydrogel. 
This improved therapeutic effect was associated with an altered 
MMP9/TIMP2 expression profile that likely contributed to the 
reduction in adverse remodeling.
In summary, fibroblasts play an important role in MI wound 
healing and therefore enhancing their function post-MI may be 
what is needed to significantly improve outcomes in patients with 
MI. Promising in vitro work suggests that fibroblasts are highly 
responsive to a variety of biomaterials and are able to adhere 
and proliferate on many of them. However, more in vivo evalu-
ation is needed in order to assess how fibroblasts will respond 
to materials in the MI setting. The stressed and changing post-
MI environment introduces infinitely more variables that need 
to be considered when selecting and tailoring biomaterials for 
implantation. Many technologies are available for the customiza-
tion of different biomaterial properties from fiber and pore size 
to mechanical properties like stiffness and elasticity, with the aim 
of better controlling fibroblast function in vivo. However, a better 
understanding of the mechanisms involved in fibroblast-material 
interactions will be needed in order to effectively apply these 
technologies.
eNDOTHeLiAL CeLLS
endothelial Cell Function
Endothelial cells line the inner lumen of all the vasculature and 
contribute to the regulation of blood flow. In larger blood vessels, 
chemical signals from the blood are detected by endothelial cells 
and communicated to the surrounding smooth muscle for the 
regulation of vasomotor tone and blood flow. For example, nitric 
oxide signaling from the endothelial cell stimulates smooth mus-
cle cells leading to vasodilation and increased blood flow (Cines 
et al., 1998; Michiels, 2003; Deanfield et al., 2007). Endothelial 
cells also respond to mechanical stimuli, such as shear strain, to 
secrete vasoactive factors that can alter the physiological function 
of distant target organs or mobilize cell populations for recruit-
ment if needed (Michiels, 2003; Chien, 2007; Deanfield et  al., 
2007). One of the most important functions of endothelial cells is 
their ability to act as a barrier to prevent the unwanted infiltration 
of foreign substances. The endothelial cell is recognized as a key to 
maintaining vascular homeostasis so that the body can function 
with optimal hemodynamics.
vascular Pathophysiology during Mi
During the hypoxia that follows MI, a significant loss of endothelial 
cells through apoptosis and necrosis occurs, much like the other 
cells of the heart. The cells that do survive experience oxidative 
stress, which severely alters endothelial cell physiology. The pres-
ence of reactive oxygen species (ROS) increases the expression 
of cell adhesion molecules and the permeability of endothelial 
cells leading to an enhanced recruitment/invasion of leukocytes 
(Lum and Roebuck, 2001). The recruited immune cells, such 
as macrophages, amplify the pro-necrotic signaling in the local 
hypoxic environment resulting in more tissue death (Nahrendorf 
et  al., 2007, 2010). The necrosis of vascular tissues means that 
even when blood flow is restored to the coronary system, the 
infarcted tissue can remain inadequately perfused, leading to 
further damage and infarct expansion. Therefore, therapies that 
limit vascular death and/or improve the regenerative capacity of 
the endothelium are expected to better preserve cardiac function 
post-MI.
enhancing endothelial Cell Function with 
Biomaterials
Angiogenesis is a critical component of the healing process 
post-MI. Without adequate revascularization, hypoxic or anoxic 
conditions persist in the cardiac tissue leading to more cell death 
over time. Furthermore, the regeneration of blood vessels is 
paramount to the regeneration of the heart as a whole. Blood 
vessels are required to transport oxygen and nutrients to the 
cells, as well as to remove toxic waste products. Many biomateri-
als have shown promise as a strategy to improve the function, 
proliferation, and survival of endothelial cells in an attempt boost 
angiogenesis post-MI.
Several studies have reported on the performance of an 
electrospun nanofiber scaffold composed of poly(l-lactide-co-ϵ-
caprolacetone) [P(LLA-CL)] (Mo et al., 2004; Xu et al., 2004; He 
et al., 2005). The biomaterial is fabricated such that the – CL unit 
is highly organized on each nanofiber of the scaffold. In vitro, 
smooth muscle cells and endothelial cells seeded onto the matrix 
adhered after 1 day and significant proliferation was observed by 
day 7 (Mo et al., 2004). When the alignment of the material was 
made to more closely resemble the native formation of typical 
arteries, smooth muscle cells elongated along the length of the 
nanofiber in spindle-like fashion after 5 h of culture, and after 
3 days, they appeared bi-polar indicating a contractile phenotype 
(Xu et al., 2004). Although not dealing directly with endothelial 
cells, this study shows that the P(LLA-CL) material is capable 
of supporting cells needed for blood vessel growth/maturation 
during angiogenesis. In another study, the P(LLA-CL) was used 
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as a nanofiber mesh, which was coated in type 1 collagen prior to 
seeding with human coronary artery endothelial cells (HCAECs) 
(He et al., 2005). HCAECs adopted a flattened, more spread out 
morphology on the collagen-coated network than on the uncoated 
network, which is indicative of an adherent phenotype necessary 
for vascular grafting. While in  vitro testing yields important 
information about endothelial cell-biomaterial interactions, 
in vivo studies are needed to properly evaluate the potential for 
a biomaterial to support blood vessel regeneration. Many factors 
in  vivo could affect the performance of a biomaterial, such as 
interactions with other cell types, pH changes, hypoxia, and the 
presence of degrading enzymes.
In one study, a porous bovine pericardial patch containing 
MSCs was able to enhance the function of endothelial cells 
when implanted into a right ventricular defect. Greater capillary 
growth was observed in the inner and outer layers of the MSC 
patch compared to the control patch without MSCs at 4 weeks 
post-implantation; and there was an intact layer of endothelial 
cells on the inner layer of the MSC patch, which did not occur in 
the control (Wei et al., 2006). Transplanted MSCs were shown to 
differentiate into endothelial cells and smooth muscle cells that 
contributed directly to new capillary formation; although capil-
lary density was reduced compared to the healthy myocardium. 
Similar results were obtained with injection of a fibrin glue scaf-
fold. The fibrin material limited adverse remodeling and increased 
blood vessel regeneration within the infarct zone compared to 
control BSA injections (Christman et al., 2004). In a study com-
paring fibrin, collagen type 1, and Matrigel, it was found that all 
three materials promoted angiogenesis and increased capillary 
density compared to PBS-injected control animals (Huang et al., 
2005). All the materials produced positive results that were not 
significantly different from each other. These results suggest that 
endothelial cells are a relatively invasive cell that can populate the 
MI area if provided with a suitable substrate or environment, such 
as a biomaterial scaffold.
The supplementation of a biomaterial with growth factors is an 
approach that has been tested often for enhancing vascular regen-
eration. For example, in one study, a collagen hydrogel composed 
of type I and type 3 collagen was crosslinked and conjugated 
with VEGF prior to subcutaneous injection, and tested against 
pure collagen, crosslinked collagen, and VEGF-collagen (He 
et al., 2011). There was greater cell infiltration in the crosslinked 
VEGF-conjugated collagen compared to pure collagen at 1-week 
post implantation. At 2 weeks, the number of microvessels in the 
crosslinked VEGF conjugated collagen was significantly greater 
than all other groups. It was found that there was a greater amount 
of VEGF immobilized by crosslinking, and that angiogenesis was 
sustained for a longer period of time compared to the other three 
groups. In a similar strategy, collagen patches (Ultrafoam™ col-
lagen sponge scaffolds; Davol) with VEGF covalently bound at 
low or high concentration were implanted into MI hearts. Both 
materials were able to preserve ventricular wall thickness, with 
the greater thickness observed in the high VEGF biomaterial 
(Miyagi et  al., 2011). After patch engraftment to the infarcted 
region, bone marrow cells were injected to the biomaterial-treated 
heart; increased retention and proliferation of the transplanted 
cells, as well as greater vascular density was seen in the high VEGF 
biomaterial group compared to control patches and low VEGF 
patches. Similar to VEGF, the inclusion of other angiogenic factors, 
such as FGF-2, IGF-1, and HGF, in a biomaterial has also led to 
increased vascularization of cardiac tissue. It has been shown that 
the sequential release of IGF-1 followed by HGF from an affinity-
binding alginate hydrogel was able to increase angiogenesis and 
mature blood vessel formation in the MI heart more so than single 
growth factor control gels or gels without growth factors, suggest-
ing that the timing and selection of growth factors for delivery is 
an important consideration (Ruvinov et al., 2011). Another group 
developed a poly(N-isopropylacrilamide-co-propylacrylic acid-
co-propyl acrylate) [p(NIPAAm-co-PAA-co-BA)] material that 
was supplemented with biotinylated FGF before being injected 
into infarcted hearts. A 10-fold increase in FGF retention was 
observed in the p(NIPAAm-co-PAA-co-BA)-FGF group com-
pared to animals that received FGF delivered in saline, which led 
to ~40% greater arteriolar and capillary density (Garbern et al., 
2011). After 28 days, there was a twofold increase in perfusion 
of the infarcted area in hearts treated with the polymer + FGF, 
whereas controls showed no improvement in perfusion. Overall, 
many studies have demonstrated that growth factor supplemen-
tation of a biomaterial is a promising therapeutic approach for 
the regeneration of blood vessels.
Autologous in  vitro tissue engineering is another technique 
under investigation for generating vascularized tissue. With this 
type of biomaterial, cells are isolated from the donor and cultured 
in  vitro in a tissue-engineered scaffold to generate new tissue 
that can later be implanted back into the host. In one example, 
human osteoblasts and human micro-capillary endothelial cells 
were seeded onto a silk fibroin scaffold in vitro. This resulted in 
the formation of a micro-capillary network intertwined with 
scaffold and osteoblast cells (Unger et  al., 2007). To test its 
functionality, the biomaterial was implanted subcutaneously into 
immunodeficient mice. After 14 days, the scaffold was removed 
and it was determined that the micro-capillary network that was 
formed in vitro successfully connected with the host vasculature 
and became perfused. The silk fibroin scaffold also promoted the 
migration of host vasculature into the biomaterial (Unger et al., 
2010). This demonstrates the viability of in vitro pre-vascularized 
biomaterials as a strategy to quickly restore vascular networks 
within damaged tissues. In a more cardiac-relevant model, a 
hydrogel made from decellularized porcine heart ECM was 
engineered to gel at physiological temperature and self-assemble 
into a complex structure post-injection (Singelyn et  al., 2009). 
Injection of the cardiac mimicking biomaterial lead to signifi-
cantly increased arteriole density compared to fibrin controls.
There are many promising biomaterial strategies that have 
demonstrated success in improving the function of endothelial 
cells and stimulating revascularization in  vitro and in  vivo. 
Despite this, more studies are needed that address the organiza-
tion, maturation and persistence of the newly formed vascular 
networks in relevant models of coronary artery disease.
FUTURe DiReCTiONS
Emerging technologies such as 3D printing and nanoparticles 
may provide the opportunity for new biomaterial manufacturing 
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techniques to further advance the field of regenerative medicine. 
One group has demonstrated success with bioprinting a 3D 
alginate/gelatin hydrogel network. Cells embedded within this 
construct were capable of controlling the degradation of the 
biomaterial in the presence of sodium citrate, which in turn 
allowed the cells to have superior proliferation and differentia-
tion (Wu et  al., 2016). Another group created bioink derived 
from decellularized adipose tissue (DAT) to make 3D printed 
biomaterials (Pati et al., 2015). It was shown that human adipose 
tissue-derived mesenchymal stem cells encapsulated within the 
DAT printed biomaterial matured normally with high viability 
without the addition of supplemental adipogenic factors. Upon 
sub-cutaneous implantation in mice, the cell-seeded construct 
supported positive tissue infiltration and constructive remod-
eling, and was non-inflammatory. Physical properties of a 
material, such as substrate modulus, may be specifically tailored 
by using 3D printing. Guo et al. showed that a poly(ester ure-
thane) biomaterial with a substrate modulus similar to collagen 
fibers was able to reduce inflammation, increase angiogenesis, 
and decrease fibrosis when used to treat dermal wounds. The 
material elicited a down-regulation of Wnt/β-catenin signaling 
in fibroblasts, and increased M2 polarization of macrophages, 
demonstrating their ability to promote a regenerative, rather 
than a fibrotic/scar response in host cells (Guo et al., 2015). In 
a cardiac model, a 3D printed gelatin/HA biomaterial loaded 
with human cardiac-derived progenitor cells was applied post-
MI in mice leading to a reduction in adverse remodeling and 
preservation of cardiac function (Gaetani et  al., 2015). The 
transplanted cells exhibited enhanced survival over a period of 
4 weeks, as well as increased expression of cardiac and vascular 
differentiation markers.
Another increasingly studied approach for regenerative 
medicine involves the use of nanoparticles. For example, Baei 
et  al. used gold nanoparticles in combination with a chitosan 
hydrogel to create a material with the potential to support electri-
cal conduction in electro-active tissues. MSCs were seeded onto 
the gold nanoparticles-chitosan hydrogel for 14 days and it was 
found that the biomaterial supported normal cell metabolism, 
migration and proliferation as well as increased cardiomyogenic 
differentiation (Baei et al., 2016). In another application, decel-
lularized vascular tissue was conjugated with gold nanoparticles 
and used in patch angioplasty of the carotid artery in mice. 
The vascular patch with gold nanoparticles showed increased 
endothelial regeneration and a normal healing response with 
excellent tissue integration (Ostdiek et  al., 2016). Both 3D 
printing and nanoparticle technology have shown promise in 
the regenerative field but like other biomaterial approaches, 
they require more research and optimization before they can 
be clinically employed.
CONCLUSiON
It has been shown that biomaterials are capable of enhancing the 
repair/regenerative capacity of many different cell types (sum-
marized in Table 3). Knowing that different cells are dominant 
as the infarct evolves through its inflammatory, proliferative, and 
maturation phases will help in designing and optimizing materi-
als for application at different time-points post-MI. A biomaterial 
can influence cells either directly or indirectly through down-
stream signaling and knowing these signaling mechanisms will 
also allow for greater control of the healing process. This review 
highlights the abilities of biomaterials to enhance cells and repair 
by focusing on each cell type individually; however, materials are 
likely to affect more than a single cell type when administered 
into the MI heart so that multiple repair processes can be targeted 
simultaneously. It may also be that multiple biomaterial strategies 
will need to be applied in combination to promote appropriate 
repair responses from the different cell types. With improving 
engineering technologies, it is possible to customize biomaterials 
to possess specific physical and biological parameters in order to 
optimize host cell function. Successful biomaterial therapy will be 
able to improve cardiac function at a cellular level, which would 
improve patient outcomes post-MI.
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TABLe 3 | Cell responses and associated functional benefits that have been observed with different biomaterial therapy strategies.
Cardiomyocytes Macrophages Fibroblasts endothelial Cells
Cellular improvements ↓Apoptosis ↑Recruitment ↑Proliferation ↑Proliferation
↑Proliferation ↑M2 polarization ↑Migration ↑Cell survival
↑Recruitment of cardiac repair cells ↓Myofibroblast activity ↑Vessel retention
↑Ca2+ conduction ↑Cell localization
Functional benefits ↓Remodeling ↓MMP Activity ↓ Fibrosis ↑Formation of neocapillaries
↓Scar expansion ↑Neovascularization ↓Vessel remodeling
↑LVEF ↑Vessel regeneration and angiogenesis
↑Ventricular wall thickness ↑Vascular density
↑Fractional shortening ↑ Perfusion
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